Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Improvements analyze found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://hilaryn838xdd7.luwebs.com/profile